InsiderTrades.com logo
“Retirement Secret” Showed 995% Gain Last Time We Shared It
From Stansberry Research   |   Ad
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Find out why right here (and see what you can do to get in too with just a few dollars).
Todd Shegog net worth and biography
  • Phone
  • Email
  • Website

Todd Shegog Biography and Net Worth

CFO of Forma Therapeutics
Todd joined Forma in September 2019 with over 25 years of financial experience in the biotechnology and pharmaceutical industries. He most recently served as chief financial officer for Synlogic (Nasdaq: SYBX), where he directed the company’s financial strategy and management as well as facilities and information systems. Prior to Synlogic, Todd served as senior vice president and chief financial officer at Forum Pharmaceuticals, where he was responsible for finance, operations and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer’s disease. Prior to Forum, Todd was the chief financial officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company’s financial resources, corporate planning, financial reporting and compliance. Todd earned a Bachelor of Science degree in electrical engineering from Lafayette College and an MBA from the Tepper School of Management at Carnegie Mellon University.

How old is Todd Shegog?

Mr. Shegog is currently 56 years old. There are 6 older executives and no younger executives at Forma Therapeutics. The oldest executive at Forma Therapeutics is Dr. David N. Cook Ph.D., Sr. VP & Chief Scientific Officer, who is 64 years old. Learn More on Todd Shegog's age.

How do I contact Todd Shegog?

The corporate mailing address for Mr. Shegog and other Forma Therapeutics executives is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. Forma Therapeutics can also be reached via phone at 617-679-1970 and via email at [email protected]. Learn More on Todd Shegog's contact information.

Has Todd Shegog been buying or selling shares of Forma Therapeutics?

Todd Shegog has not been actively trading shares of Forma Therapeutics during the last quarter. Most recently, Todd Shegog sold 5,687 shares of the business's stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $9.78, for a transaction totalling $55,618.86. Learn More on Todd Shegog's trading history.

Who are Forma Therapeutics' active insiders?

Forma Therapeutics' insider roster includes Patrick Kelly (SVP), Frank Lee (CEO), Jeannette Potts (Insider), and Todd Shegog (CFO). Learn More on Forma Therapeutics' active insiders.

Todd Shegog Insider Trading History at Forma Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2022Sell5,687$9.78$55,618.86View SEC Filing Icon  
See Full Table

Todd Shegog Buying and Selling Activity at Forma Therapeutics

This chart shows Todd Shegog's buying and selling at Forma Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Forma Therapeutics Company Overview

Forma Therapeutics logo
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Read More

Today's Range

Now: $20.01
Low: $20.01
High: $20.01

50 Day Range

MA: $20.00
Low: $19.91
High: $20.01

2 Week Range

Now: $20.01
Low: $4.95
High: $20.68

Volume

1 shs

Average Volume

847,595 shs

Market Capitalization

$957.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
“Retirement Secret” Showed 995% Gain Last Time We Shared It
From Stansberry Research   |   Ad
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Find out why right here (and see what you can do to get in too with just a few dollars).